Lymphoma, Mantle-Cell: all 810 studies
Page 4 of 9. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.
- Study of Bortezomib in Combination With Cyclophosphamide and RituximabCompletedNCT00958256Phase 2Results posted
- Study of Repeat Intranodal Injections of Ad-ISF35TerminatedNCT00942409Phase 2Results posted
- Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
- Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell LymphomaCompletedNCT00891839Phase 2Results posted
- Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT00878254Phase 2Results posted
- Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT StudyCompletedNCT00877006Phase 3Results posted
- A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT00875667Phase 2Results posted
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell LymphomaCompletedNCT00867529Phase 2Results posted
- Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
- A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell LymphomaTerminatedNCT00843050Phase 2Results posted
- Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's LymphomaCompletedNCT00807495Phase 2Results posted
- Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2Results posted
- Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerCompletedNCT00789776Phase 1/2Results posted
- Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell LymphomasCompletedNCT00783367Phase 2Results posted
- Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's LymphomaCompletedNCT00764517Phase 2Results posted
- A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" TrialCompletedNCT00737529Phase 2Results posted
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerCompletedNCT00723099Phase 2Results posted
- Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00722137Phase 3Results posted
- Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseCompletedNCT00719888Phase 2Results posted
- Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell MalignanciesTerminatedNCT00714259Phase 2/3Results posted
- Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell LymphomaCompletedNCT00711828Phase 2Results posted
- Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00703664Phase 2Results posted
- Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® TherapyCompletedNCT00702052Phase 2Results posted
- Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]CompletedNCT00700258Results posted
- Study of MLN8237 in Participants With Advanced Hematological MalignanciesCompletedNCT00697346Phase 1Results posted
- Ph2 Gem/Nov/Rituxan Rel/Ref MantleCellCompletedNCT00656084Phase 2Results posted
- Oral Clofarabine for Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT00644189Phase 1/2Results posted
- Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaCompletedNCT00633594Phase 1/2Results posted
- Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After RituximabCompletedNCT00609869Phase 2Results posted
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaCompletedNCT00601718Phase 1/2Results posted
- In-Vivo Activated T-Cell Depletion to Prevent GVHDTerminatedNCT00594308Not applicableResults posted
- Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell LymphomaCompletedNCT00581854Phase 2Results posted
- Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell LymphomaCompletedNCT00581776Phase 2Results posted
- VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell LymphomaCompletedNCT00571493Phase 1/2Results posted
- Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00553644Phase 2Results posted
- Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
- High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicableResults posted
- Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCLCompletedNCT00490529Phase 2Results posted
- Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell LymphomaCompletedNCT00477412Phase 1/2Results posted
- A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.CompletedNCT00472420Phase 2Results posted
- R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell LymphomaCompletedNCT00450801Phase 2Results posted
- Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell LymphomaCompletedNCT00445341Phase 1/2Results posted
- Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin LymphomaCompletedNCT00438880Phase 1/2Results posted
- Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell LymphomaCompletedNCT00433537Phase 2Results posted
- An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.CompletedNCT00420056Phase 1Results posted
- Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
- Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell LymphomaCompletedNCT00401817Phase 2Results posted
- FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00383565Phase 2Results posted
- S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00376961Phase 2Results posted
- Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell LymphomaCompletedNCT00310037Phase 2Results posted
- Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell LymphomaCompletedNCT00294632Phase 1/2Results posted
- Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT00288067Phase 1/2Results posted
- Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00278408Phase 3Results posted
- Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's LymphomaCompletedNCT00278161Phase 2Results posted
- A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow TransplantationTerminatedNCT00275262Phase 2Results posted
- Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's LymphomaCompletedNCT00253630Phase 2Results posted
- Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's LymphomaCompletedNCT00225212Phase 2Results posted
- Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's LymphomaCompletedNCT00201877Phase 2Results posted
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHDCompletedNCT00186628Phase 2Results posted
- Phase II Study of RT-PEPC in Relapsed Mantle Cell LymphomaCompletedNCT00151281Phase 2Results posted
- Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00119392Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
- 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's LymphomaCompletedNCT00117988Phase 2Results posted
- Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)CompletedNCT00117598Phase 3Results posted
- EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell LymphomaCompletedNCT00114738Phase 2Results posted
- Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedNCT00112723Phase 1/2Results posted
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109967Phase 2Results posted
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00105001Phase 2Results posted
- Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell LymphomaCompletedNCT00101101Phase 2Results posted
- MDX-010 in Treating Patients With Recurrent or Refractory LymphomaTerminatedNCT00089076Phase 1/2Results posted
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
- Oral Enzastaurin in Participants With Relapsed Mantle Cell LymphomaCompletedNCT00088205Phase 2Results posted
- Tipifarnib in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00082888Phase 2Results posted
- Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00075478Phase 3Results posted
- Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00073918Phase 2Results posted
- Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesCompletedNCT00072514Phase 2Results posted
- Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00058019Phase 2Results posted
- Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedNCT00054639Phase 2Results posted
- Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
- S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell LymphomaCompletedNCT00041132Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
- Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDSCompletedNCT00025662Phase 2Results posted
- Bortezomib in Treating Patients With Lymphoproliferative DisordersCompletedNCT00023764Phase 2Results posted
- Chemotherapy Plus Vaccination to Treat Mantle Cell LymphomaCompletedNCT00005780Phase 2Results posted
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaActive, not recruitingNCT06667687Phase 1
- CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell NeoplasmsStatus unknownNCT06593145Phase 1
- A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin LymphomaTerminatedNCT06561425Phase 1/2
- GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT06522386Phase 2
- Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT06504199Phase 2
- Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic MalignanciesTerminatedNCT06343376Phase 1
- Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomasActive, not recruitingNCT06300528Phase 2
- Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)Active, not recruitingNCT06285422Phase 1
- A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT06256484Phase 1
- Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaActive, not recruitingNCT06253663Phase 2
- A Study of Glofitamab and Lenalidomide in People With Mantle Cell LymphomaActive, not recruitingNCT06192888Phase 1
- TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)TerminatedNCT06106841Phase 1/2
- Evaluating Different Doses of Orelabrutinib in MCLCompletedNCT05978739Phase 2
- A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive, not recruitingNCT05951959Phase 2
- Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell TherapyWithdrawnNCT05936229Phase 1/2